PTK7: an underestimated contributor to human cancer.

IF 3.5 3区医学 Q2 ONCOLOGY

Frontiers in Oncology Pub Date : 2024-10-15 eCollection Date: 2024-01-01 DOI:10.3389/fonc.2024.1448695

Zhipeng Jin, Tianyu Guo, Xue Zhang, Xin Wang, Yefu Liu

引用次数: 0

Abstract

Protein tyrosine kinase 7 (PTK7) is an evolutionarily conserved transmembrane receptor and a specialized tyrosine kinase protein lacking kinase activity. PTK7 has been found to be strongly associated with a variety of diseases, including cancer. In this review, we will provide a comprehensive overview of the involvement of PTK7 in human cancer, focusing on the changing research landscape of PTK7 in cancer research, the molecular mechanisms of PTK7 involved in cancer progression, the targetability of PTK7 in cancer therapy, and the potential application of PTK7 in cancer management, thus demonstrating that PTK7 may be an underestimated contributor to human cancer.

查看原文本刊更多论文

PTK7：被低估的人类癌症诱因。

蛋白酪氨酸激酶7（PTK7）是一种进化保守的跨膜受体，也是一种缺乏激酶活性的特化酪氨酸激酶蛋白。研究发现，PTK7 与包括癌症在内的多种疾病密切相关。在这篇综述中，我们将全面概述 PTK7 参与人类癌症的情况，重点关注 PTK7 在癌症研究中的研究格局变化、PTK7 参与癌症进展的分子机制、PTK7 在癌症治疗中的靶向性，以及 PTK7 在癌症管理中的潜在应用，从而证明 PTK7 可能是被低估的人类癌症贡献者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Oncology Biochemistry, Genetics and Molecular Biology-Cancer Research

CiteScore

6.20

自引率

10.60%

发文量

6641

审稿时长

14 weeks

期刊介绍： Cancer Imaging and Diagnosis is dedicated to the publication of results from clinical and research studies applied to cancer diagnosis and treatment. The section aims to publish studies from the entire field of cancer imaging: results from routine use of clinical imaging in both radiology and nuclear medicine, results from clinical trials, experimental molecular imaging in humans and small animals, research on new contrast agents in CT, MRI, ultrasound, publication of new technical applications and processing algorithms to improve the standardization of quantitative imaging and image guided interventions for the diagnosis and treatment of cancer.